Eva Papp
Roche (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Computational Drug Discovery Methods, Synthesis and biological activity, Monoclonal and Polyclonal Antibodies Research, Adenosine and Purinergic Signaling
Most-Cited Works
- → Characterization of human type I and type II IMP dehydrogenases.(1993)422 cited
- → Molecular Mechanism of the Syk Activation Switch(2008)160 cited
- → Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase(2003)95 cited
- → Pamapimod, a Novel p38 Mitogen-Activated Protein Kinase Inhibitor: Preclinical Analysis of Efficacy and Selectivity(2008)78 cited
- → Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase(2011)74 cited
- → Structural Insights for Design of Potent Spleen Tyrosine Kinase Inhibitors from Crystallographic Analysis of Three Inhibitor Complexes(2009)68 cited
- → Discovery of S-[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an Orally Bioavailable and Highly Selective Inhibitor of p38 Map Kinase(2006)64 cited
- → Structure−Activity Relationships for Inhibition of Inosine Monophosphate Dehydrogenase by Nuclear Variants of Mycophenolic Acid(1996)49 cited
- → 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: Design and development to a highly selective lead(2011)27 cited
- → Steady State Kinetics of Spleen Tyrosine Kinase Investigated by a Real Time Fluorescence Assay(2007)23 cited